Mangafodipir

Mangafodipir
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pregnancy
category
  • Not to be used
Routes of
administration		 Intravenous infusion
ATC code
Pharmacokinetic data
Bioavailability NA
Protein binding 27% (manganese)
Negligible (DPDP)
Elimination half-life 20 minutes (manganese)
50 minutes (DPDP)
Excretion Renal and fecal (manganese)
Renal (DPDP)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C22H28MnN4O14P2
Molar mass 689.362 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Mangafodipir (sold under the brand name Teslascan as mangafodipir trisodium) is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver. It has two parts, paramagnetic manganese (II) ions and the chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Normal liver tissue absorbs the manganese more than abnormal or cancerous tissue. The manganese shortens the longitudinal relaxation time (T1), making the normal tissue appear brighter in MRIs. This enhanced contrast allows lesions to be more easily identified.

Mangafodipir was withdrawn from the US market in 2003[1] and the European market in 2012.[2]

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) participate in pathological tissue damage. Mitochondrial manganese superoxide dismutase (MnSOD) normally keeps ROS and RNS in check. During development of mangafodipir as an MRI contrast agent, it was discovered that it possessed MnSOD mimetic activity. Mangafodipir has been tested as a chemotherapy adjunct in cancer patients and as an adjunct to percutaneous coronary intervention in patients with myocardial infarctions, with promising results.[3] Whereas MRI contrast depends on release of Mn2+, the MnSOD mimetic activity depends on Mn2+ that remains bound to DPDP. Calmangafodipir [Ca4Mn(DPDP)5] (brand name PledOx) is stabilized with respect to Mn2+ and has improved therapeutic activity.[3] Calmangafodipir is being explored as a chemotherapy adjunct in cancer patients.

References

  1. ↑ "January 2005: Additions and Deletions to the Drug Product List". U.S Food and Drug Administration.
  2. ↑ "Teslascan (mangafodipir): Withdrawal of the marketing authorisation in the European Union" (PDF). European Medicines Agency.
  3. 1 2 Karlsson, Jan Olof G (April 2015). "Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties". Drug Discov Today. 20: 411–421. doi:10.1016/j.drudis.2014.11.008.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.